Can you provide the upcoming earnings date for AEROVATE THERAPEUTICS INC?
AEROVATE THERAPEUTICS INC (AVTE) will report earnings on 2025-05-12, after the market close.
AEROVATE THERAPEUTICS INC (AVTE) Forecast, Price Target & Analyst Ratings
NASDAQ:AVTE • US0080641071
Current stock price
2.68 USD
0 (0%)
At close:
2.6505 USD
-0.03 (-1.1%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AEROVATE THERAPEUTICS INC (AVTE).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 12, 2025
- Period
- Q1 / 2025
- EPS Estimate
- -$0.24
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $2.68 to mean target of N/A, Based on 9 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
48.89%
AVTE was analyzed by 9 analysts. The buy percentage consensus is at 49. So analysts seem to be rather neutral about AVTE.
In the previous month the buy percentage consensus was at a similar level.
AVTE was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-06-18 | TD Cowen | Downgrade | Buy -> Hold |
| 2024-06-18 | Guggenheim | Downgrade | Buy -> Neutral |
| 2024-06-18 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2024-06-18 | Evercore ISI Group | Downgrade | Outperform -> In-Line |
| 2024-06-17 | BTIG | Downgrade | Buy -> Neutral |
| 2024-06-17 | Jefferies | Downgrade | Buy -> Hold |
| 2024-06-06 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-05-22 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-05-14 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-04-01 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2023-03-01 | Guggenheim | Initiate | Buy |
| 2022-12-06 | BTIG | Upgrade | Neutral -> Buy |
| 2022-08-16 | BTIG | Downgrade | Buy -> Neutral |
| 2022-02-11 | BTIG | Initiate | Buy |
| 2021-07-26 | Cowen & Co. | Initiate | Outperform |
| 2021-07-26 | Wedbush | Initiate | Outperform |
| 2021-07-26 | Evercore ISI Group | Initiate | Outperform |
| 2021-07-26 | Jefferies | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 12, 2025
- Period
- Q1 / 2025
- EPS Estimate
- -$0.24
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 70.51%
- Number of Analysts
- 5
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
18.64%
Next Earnings Summary
AVTE is expected to report earnings on 5/12/2025. The consensus EPS estimate for the next earnings is -0.24 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2025 - 2032
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |||||||
| EBITDA YoY % growth | -3.33M | -8.89M -166.97% | -23M -158.72% | -53.17M -131.17% | -81.313M -52.93% | -74.014M 8.98% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -3.33M | -8.89M -166.97% | -23.02M -158.94% | -53.24M -131.28% | -81.409M -52.91% | -74.296M 8.74% | N/A 58.47% | N/A 35.22% | N/A -4.71% | N/A -25.28% | N/A -2.68% | N/A -2.70% | N/A -2.73% | N/A -2.74% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.11 -28.69% | -2.88 -36.49% | -2.44 15.28% | N/A 74.29% | N/A -300.65% | N/A 71.59% | N/A -391.43% | N/A 84.01% | N/A 712.73% | N/A 78.04% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.24 70.51% | -0.18 79.05% | -0.18 67.21% | -0.12 35.58% | -0.37 -52.29% | -0.17 6.04% | -0.18 1.11% | -0.21 -74.58% |
| Revenue Q2Q % growth | ||||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -10.2M 58.57% | -8.772M 66.47% | -6.783M 60.36% | -5.1M 20.35% | -3.672M 64.00% | -3.774M 56.98% | -3.774M 44.36% | -3.876M 24.00% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
19.52%
EPS Next 5 Year
12.10%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
AEROVATE THERAPEUTICS INC / AVTE Forecast FAQ
What are the consensus estimates for AVTE stock next earnings?
The consensus EPS estimate for the next earnings of AEROVATE THERAPEUTICS INC (AVTE) is -0.24 USD and the consensus revenue estimate is 0 USD.
How do analysts rate AEROVATE THERAPEUTICS INC (AVTE)?
The consensus rating for AEROVATE THERAPEUTICS INC (AVTE) is 48.8889 / 100 . This indicates that analysts generally have a neutral outlook on the stock.